Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Mueller D, Krug S, Majumder M, Gress T, Rinke A,

Keywords: NEN, DTIC, MGMT,

#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience

Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Fraenkel M, Barak D, Mueller-Brand J, Krausz Y, Glaser B,

Keywords: PRRT, chronic complications, GEPNET,

#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas

Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grozinsky-Glasberg S, Barak D, Fraenkel M, Müeller J, Shimon I,

Keywords: PRRT, malignant gastrinoma, treatment, anti-tumor effect ,